Search

everythinglearnresearchcommunity

for

Search:↓

Men who start losing hair at age 30 may have a lower risk of prostate cancer.

Prostate cancer is common, but risk can be reduced by avoiding smoking, unhealthy diet, inactivity, certain medications, and risky jobs.

Diabetes may lower the risk of prostate cancer.

No link was found between hair patterns and prostate cancer risk in South Indian men.

WNT10B is linked to cancer development and affects survival and disease progression in various cancers.

5-alpha reductase inhibitors are generally safe but can cause sexual side effects and require patient education on risks.

Different prostate cancer treatments have similar risks of secondary cancers and related mortality when considering patient age and smoking history.

Finasteride might lower the risk of low-grade prostate cancer but not high-grade cancer, while alpha-blockers might reduce high-grade cancer risk.

Male pattern baldness may predict prostate cancer risk.

Taking 5-alpha reductase inhibitors does not increase the risk of breast cancer in men.

Taking 5-alpha reductase inhibitors does not increase breast cancer risk in men.

The document suggests that blocking sweat glands with antiperspirants might allow skin-generated hormones to be absorbed, possibly increasing breast and prostate cancer risk.

Opioid use may lower PSA levels, suggesting a possible role in prostate cancer control; PSA testing is useful for detecting prostate cancer; serum triglycerides are not linked to prostate cancer risk; and higher urethral PSA levels may be associated with local hormone activity.

Taking 5α-reductase inhibitors does not significantly increase the risk of breast cancer in men.

Certain plasma proteins are linked to prostate cancer risk and could help in early detection and treatment.

Being obese and eating too many calories may increase the risk of kidney cancer, but physical activity doesn't seem to affect this risk.

Advocacy groups should avoid marketing partnerships that may imply drug endorsements.

The document concludes that various medications and treatments can have significant, sometimes adverse, effects on health outcomes.

Testosterone's health effects are complex and not definitively understood.

Finasteride effectively treats male hair loss, increasing length and thickness.

Finasteride helps improve treatment for benign prostatic hyperplasia.

The conclusion is that treatments like finasteride and minoxidil can prevent baldness progression and improve hair density, but more research is needed on other therapies.

The document concludes that better research methods are needed in men's sexual health to provide stronger evidence and improve patient care.

ERG increases SOX9, promoting prostate cancer growth and invasion.

Finasteride use is not clearly linked to an increased risk of male breast cancer.

Androgen deprivation therapy doesn't lower the risk of death from COVID-19 in prostate cancer patients.

Androgenetic alopecia may indicate higher risk for certain diseases and mental health issues.

Men with vertex baldness may have a higher risk of developing prostate cancer, but more research is needed to confirm this.

Finasteride treats hair loss and reduces prostate cancer risk.

Dutasteride is effective for treating prostate enlargement and reducing related surgery risk, but is not approved for preventing prostate cancer.